Be sure to check our sister interview main ratings news website

Deltex Medical Group plc is in the April edition of the British Journal of Anaesthesia

Deltex Medical Group plc (LON:DEMG), the global leader in Oesophageal Doppler Monitoring (“ODM”), announced today that it intends to release its results for the year ended 31 December 2017 on 9 May 2018.

Further to the announcement of the online publication of the results of the FEDORA trial on 1 March 2018, the Company notes that the study was included in the April print edition of the British Journal of Anaesthesia.

A recorded lecture on the FEDORA trial by Professor Monty Mythen is available at no charge at https://www.topmedtalk.com/journal-club-the-fedora-trial/

Click to view all articles for the EPIC:
Or click to view the full company profile:
    Facebook
    Twitter
    LinkedIn
    Deltex Medical Group Plc

    More articles like this

    Deltex Medical Group Plc

    Deltex Medical Group plc investor event 11th September

    31st August 2017

    Deltex Medical Group plc (LON:DEMG), the global leader in Oesophageal Doppler Monitoring, has told DirectorsTalk that it will be hosting an investor event on 11 September 2017 following the publication of its interim results for the

    Deltex Medical Group Plc

    Deltex Medical, Nigel Keen Chairman Statement in full

    9th June 2017

    At the Annual General Meeting of Deltex Medical Group plc (LON:DEMG), the global leader in oesophageal Doppler monitoring (ODM), to be held today the Company’s Chairman, Nigel Keen, will make the following statement: The Company is

    Deltex Medical Group Plc

    Deltex Medical’s New Monitoring Platform Module

    4th May 2017

      Ewan Phillips, Chief Executive Officer of Deltex Medical Group plc (LON:DEMG) tells Proactive Investors they’ve launched a non-invasive High Definition Impedance Cardiography (HD-ICG) module in the UK.

    Deltex Medical Group Plc

    INTERVIEW: Deltex Medical Group Plc Looking pretty good

    27th January 2017

    Deltex Medical Group Plc (LON:DEMG) CEO Ewan Phillips talks to DirectorsTalk about the benefits of the South Korean health authorities decision to increase the range of medical conditions for which they will reimburse the cost of

    © 2023 – DirectorsTalk. All rights reserved. Reproduction in whole or in part, in any form or medium without express written permission is prohibited.